Engineering Cardiac Tissue for Regeneration and Drug Development
The ‘valley of death’ in scientific parlance refers to the time period where biomedical discovery in the laboratory fails to result in a cure for a disease. While the last…
A Phase I, Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes in PaTients with ChrOnic Ischemic Left VentRicular Dysfunction (HECTOR)
Dr. Wu and his team at Stanford University will use hESCs to generate cardiomyocytes (CM), a type of cell that makes up the heart muscle. The newly created hESC-CMs will…
Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction
In this trial, Capricor Therapeutics used donor cells derived from the heart to treat patients at risk for developing heart failure after a heart attack. In previous clinical studies, the…
Modulating cardiac myosin heavy chain isoform expression for treating cardiomyopathies
Research Objective To discover CRISPR-based genetic strategies that will directly and therapeutically modify cardiac myosin heavy chain isoform expression to treat HF and cardiomyopathies. Impact Heart Failure and Cardiomyopathies Major…
Novel Lipid Nanoparticles for Enhancing eNOS Synthesis for Cardioprotection Post Myocardial Infarction
Research Objective Our therapeutic candidate is a lipid nanoparticle that delivers a therapeutic dose of mRNA to the human heart, which transiently transfects of cells within the heart to improve…
Modified RNA-Based Gene Therapy for Cardiac Regeneration Through Cardiomyocyte Proliferation
Research Objective Efficacious and safe intramyocardial delivery of modified mRNA encoding cell cycle regulators as a gene therapy for cardiac regeneration through resident cardiomyocyte proliferation. Impact This project would provide…
Cardiac Reprogramming Gene Therapy for Post-Myocardial Infarction Heart Failure
Research Objective The candidate is a gene therapy that delivers cardiac reprogramming factors to convert resident cardiac fibroblasts into functioning cardiac muscle. Thus, it is a regenerative cardiac gene therapy.…
New noncoding RNA chemical entity for heart failure with preserved ejection fraction.
Research Objective Modified synthetic noncoding RNA molecule Impact Heart failure with preserved ejection fraction Major Proposed Activities Lead optimizationPerform extensive preclinical testing and select a therapeutic candidate.Develop and test preliminary…